

# Toceranib (phosphate)

Catalog No: tcsc1231



## Available Sizes

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

874819-74-6

**Formula:**

$C_{22}H_{28}FN_4O_6P$

**Pathway:**

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

**Target:**

VEGFR;PDGFR

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 2.46 mg/mL (4.98 mM; Need ultrasonic and warming); H2O :

**Alternative Names:**

PHA 291639;SU11654

**Observed Molecular Weight:**

494.45


## Product Description

Toceranib phosphate is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor with  $K_i$ s of 5 and 6 nM for **PDGFR $\beta$**  and **Flk-1/KDR**, respectively.

IC50 & Target: Ki: 6 nM (Flk-1/KDR), 5 nM (PDGFR $\beta$ )<sup>[1]</sup>

**In Vitro:** Toceranib (SU11654) is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including PDGFR and Flk-1/KDR, with  $K_i$ s of 5 and 6 nM, respectively<sup>[1]</sup>. To explore mechanisms of acquired Toceranib (TOC) resistance in canine MCT, three resistant sublines are generated from the Toceranib-sensitive exon 11 ITD *c-kit* mutant C2 cell line designated TR1, TR2, and TR3. Growth of the parental C2 cells is inhibited by Toceranib in a dose-dependent manner with an IC<sub>50</sub> of 50 > 1,000 nM). Sensitivity to three other KIT RTK inhibitors is similar to the observed resistance to Toceranib. The parental line as well as all three sublines retains sensitivity to the cytotoxic agents vinblastine (VBL) and CCNU. Following 72 hr culture in the presence of increasing concentrations of Toceranib, treatment naïve, parental C2 cells detach from the culture flask and become rounded, shrunken, and clumped with increased exposure to Toceranib. In contrast, Toceranib-induced morphologic differences are not identified in the resistant sublines<sup>[2]</sup>.

**In Vivo:** Administration of Toceranib significantly decreases the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving Toceranib and cyclophosphamide (CYC) demonstrate a significant increase in serum concentrations of IFN- $\gamma$ , which is inversely correlated with Treg numbers after 6 weeks of combination treatment<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!